{"id":28535,"date":"2026-03-16T06:51:16","date_gmt":"2026-03-16T06:51:16","guid":{"rendered":"https:\/\/www.medicalbillersandcoders.com\/blog\/?p=28535"},"modified":"2026-03-16T06:51:19","modified_gmt":"2026-03-16T06:51:19","slug":"asc-margins-shrinking-in-2026","status":"publish","type":"post","link":"https:\/\/www.medicalbillersandcoders.com\/blog\/asc-margins-shrinking-in-2026\/","title":{"rendered":"Why Are ASC Margins Shrinking Despite Record Case Volume in 2026?"},"content":{"rendered":"

ASC margins are shrinking in 2026<\/strong> despite record case volume because costs are rising faster than reimbursement across four simultaneous pressure points: anesthesia stipend requirements now affecting 44% of ASCs, medical supply chain costs projected to increase 2.41%, a CMS payment update of only 2.6% against a 3.3% market basket \u2014 and prior authorization requirements now covering 46% of ASC cases creating cash flow delays that erode EBITDA<\/strong> even when claims are ultimately paid.<\/p>\n

The contradiction is structural, not cyclical: ASC volumes are projected to grow by 9% between 2023 and 2028, but growth in procedures does not translate into margin growth when the cost of delivering each case increases faster than payers reimburse for it. For ASCs collecting $1M\u2013$5M per month, closing this gap requires both operational cost discipline and revenue integrity<\/strong> infrastructure that captures every dollar of reimbursement the case volume has already earned.<\/p>\n

The Four Reasons ASC Margins Are Shrinking in 2026<\/h2>\n

Reason 1: The CMS Payment Update Does Not Cover Rising Costs<\/h3>\n

CMS finalized a 2.6% ASC payment increase for 2026 under the OPPS\/ASC Final Rule (CMS-1834-FC, effective January 1, 2026) \u2014 based on a 3.3% hospital market basket increase, reduced by a 0.7 percentage point productivity adjustment. The ASC conversion factor is $56.322, compared to $91.415 for hospital outpatient departments, a 38% gap that persists despite ASC case volumes reaching levels that justify parity in operational cost recognition.<\/p>\n

The 2.6% increase does not keep pace with the cost environment ASCs are actually operating in: medical supply chain costs are projected to increase 2.41% in 2026, labor costs remain elevated following pandemic-era wage increases that have not reversed, and anesthesia costs are rising independently of general labor inflation. For an ASC spending $800,000 per month on supplies and labor, a 2.6% reimbursement increase generates $20,800 in additional monthly revenue. The same cost pressures generate $30,000\u2013$50,000 in additional monthly expenses. The margin gap is mathematical.<\/p>\n

ASCs that fail to meet ASCQR (Ambulatory Surgical Center Quality Reporting) requirements face an additional statutory 2.0 percentage point reduction \u2014 eliminating the entire 2.6% update and then some. For an ASC collecting $3M per month, ASCQR non-compliance costs $60,000 per month in forefeited payment updates.<\/p>\n

Reason 2: Anesthesia Is Now a Variable Cost That Cannot Be Controlled<\/h3>\n

Anesthesia has become one of the most disruptive budget forces for ASCs in 2025 and 2026. The share of ASCs required to pay stipends to secure anesthesia coverage rose from 28% in 2024 to 44% in 2025 \u2014 a 57% increase in one year. In markets where anesthesia groups have consolidated or departed, stipends are not optional: without them, OR time goes unused, and case volume produces zero revenue regardless of procedure mix.<\/p>\n

The financial structure of anesthesia has deteriorated on both sides simultaneously. CMS finalized a 2.83% cut to the anesthesia conversion factor for 2025, reducing the amount anesthesia providers are reimbursed per unit while their labor costs have increased. Average anesthesia reimbursement fell 5.5% from 2019 to 2023. The result is that anesthesia groups cannot cover their costs through fee-for-service reimbursement alone \u2014 which transfers the coverage cost to the ASC in the form of stipends that did not exist in the facility’s budget three years ago.<\/p>\n

Over 90% of anesthesia costs are clinician salaries, leaving no meaningful opportunity for supply-side cost reduction. For ASCs, the choice is to absorb the stipend or cancel the case, and neither option preserves margin.<\/p>\n

Reason 3: Prior Authorization Is Consuming Revenue Before Claims Are Filed<\/h3>\n

As of 2024, prior authorization requirements now cover 46% of ASC cases, up from 42% in 2023, and the administrative burden extends well beyond the authorization itself. Cases requiring preauthorization face scheduling delays, physician time for documentation, staff time for submission and follow-up, and \u2014 when authorization is denied or delayed \u2014 case cancellations that eliminate revenue while fixed costs (OR staffing, anesthesia coverage, sterilization) have already been committed.<\/p>\n

CMS launched the WISeR (Wasteful and Inappropriate Service Reduction) Model on January 1, 2026, adding AI-assisted prior authorization requirements for 17 service categories in six states: Arizona, New Jersey, Ohio, Oklahoma, Texas, and Washington. Procedures covered include electrical nerve stimulator implants, epidural steroid injections, percutaneous vertebral augmentation, and image-guided lumbar decompression \u2014 high-volume, high-revenue categories for spine-focused ASCs in those states.<\/p>\n

Separately, commercial payer prior-authorization behavior is intensifying, independent of the WISeR pilot. ASC leaders report payers accelerating network narrowing, unilaterally cutting reimbursement, and increasing denial rates for previously approved services. For ASCs without payer\u00a0<\/strong>variance-detection<\/strong> protocols, these denials accumulate as write-offs rather than as\u00a0<\/span>recoverable revenue.<\/p>\n

Reason 4: 573 New Procedure Codes Create Revenue Risk Before They Create Revenue<\/h3>\n

CMS added 573 codes to the ASC Covered Procedures List for 2026, including significant spine, cardiovascular, and musculoskeletal procedures previously restricted to inpatient settings. This is a genuine revenue opportunity \u2014 but it creates an immediate billing risk that most ASCs are not positioned to manage.<\/p>\n

Commercial payers do not update their coverage policies on the same timeline as CMS. When a procedure moves from inpatient-only to ASC-eligible under the 2026 rule, Medicare pays it in the ASC setting immediately. UnitedHealthcare, Aetna, and BCBS may require 60\u2013180 days to update their internal coverage determinations. During that transition period, ASCs that bill newly eligible procedures without payer-specific verification receive systematic denials of medical necessity and authorization for procedures that CMS explicitly permits.<\/p>\n

For ASCs adding high-acuity spine or cardiac procedures to their service lines in 2026, the first 90\u2013180 days of billing those procedures without payer variance detection<\/strong> infrastructure in place represent a direct margin loss on the exact volume that was supposed to improve financial performance.<\/p>\n

The 2026 ASC Margin Gap: Cost Increases vs. Reimbursement Update<\/h2>\n\n\n\n\n\n\n\n\n\n\n
Cost \/ Revenue Category<\/strong><\/td>\n2026 Change<\/strong><\/td>\nDirection<\/strong><\/td>\nMonthly Impact ($3M ASC)<\/strong><\/td>\n<\/tr>\n
CMS Medicare Payment Update<\/strong><\/td>\n+2.6% (CMS-1834-FC)<\/td>\nRevenue +<\/td>\n+$78,000<\/td>\n<\/tr>\n
Medical Supply Chain Costs<\/strong><\/td>\n+2.41% projected increase<\/td>\nCost +<\/td>\n\u2212$14,460 (on $600,000 supply spend)<\/td>\n<\/tr>\n
Anesthesia Stipend (where required)<\/strong><\/td>\n44% of ASCs paying stipends; avg $15,000\u2013$40,000 per month<\/td>\nCost +<\/td>\n\u2212$15,000\u2013$40,000<\/td>\n<\/tr>\n
Prior Authorization Admin Cost<\/strong><\/td>\n46% of cases require preauth; avg $40\u2013$80 per auth in staff time<\/td>\nCost +<\/td>\n\u2212$6,000\u2013$12,000 (est. 150 cases)<\/td>\n<\/tr>\n
ASCQR Non-Compliance Penalty<\/strong><\/td>\n\u22122.0 percentage point payment reduction<\/td>\nRevenue \u2212 (if non-compliant)<\/td>\n\u2212$60,000<\/td>\n<\/tr>\n
New CPL Procedure Transition Denials<\/strong><\/td>\nCommercial payer 60\u2013180 day coverage lag on 573 new codes<\/td>\nRevenue \u2212 (temporary)<\/td>\nVariable; $20,000\u2013$80,000 exposure<\/td>\n<\/tr>\n
NET MARGIN IMPACT<\/strong><\/td>\nCMS increases absorption due to cost pressures on all sides<\/td>\nNegative for most ASCs<\/strong><\/td>\n\u2212$17,460 to \u2212$134,000 per month<\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Four Revenue Integrity Protocols That Protect ASC Margin When Volume Alone Cannot<\/h2>\n

ASC margins shrinking in 2026 have two root causes: cost increases that are largely external and not directly controllable by the facility, and revenue leakage from billing infrastructure gaps that are entirely controllable. The four protocols below address the controllable component \u2014 recovering revenue that the case volume has already generated, but the billing workflow is not capturing.<\/p>\n

Protocol 1 \u2014 ASCQR Compliance Verification. <\/strong>The 2.6% CMS payment update is the ASC’s largest single controllable revenue event in 2026. Losing it to ASCQR non-compliance costs a $3M ASC $60,000 per month. ASCQR reporting requires\u00a0the submission of specified quality measures; verifying that your EHR workflow captures the required data elements and submits them correctly to CMS is the highest-priority\u00a0risk-mitigation<\/strong><\/span>\u00a0action of the year.<\/p>\n

Protocol 2 \u2014 Payer Variance Detection on New CPL Procedures. <\/strong>For each of the 573 new CPL procedures your ASC intends to bill in 2026, verify commercial payer coverage effective dates before the first case is performed. Build a payer-specific tracking matrix showing which procedures each commercial payer has confirmed as covered in the ASC setting and which remain pending internal policy update. Bill confirmed procedures; hold newly eligible procedures on commercial claims until coverage is confirmed or document and appeal systematically.<\/p>\n

Protocol 3 \u2014 Prior Authorization Workflow Tightening. <\/strong>With 46% of cases requiring preauthorization, prior authorization failure is now a risk of case cancellation, not just a billing risk. Implement pre-scheduling authorization verification \u2014 confirm auth before the case is blocked, not after \u2014 and track authorization approval rates by payer and procedure category. Payers with approval rates below 85% on specific procedure categories warrant contract-level review, not just claim-level appeals.<\/p>\n

Protocol 4 \u2014 Implant and Device Charge Capture Reconciliation. <\/strong>As higher-acuity orthopedic, spine, and cardiac procedures migrate into ASC settings, implant cost exposure grows proportionally. Implants and surgical supplies are the most consistently misaligned ASC expense: they require immediate high-cost purchase while reimbursement is delayed, frequently reduced, bundled, or denied. Daily reconciliation between OR implant logs and submitted charges \u2014 not end-of-month batch review \u2014 is the only workflow that prevents implant revenue leakage from compounding across billing cycles.<\/p>\n

How MBC\u2019s Revenue Integrity Framework Turns Case Volume Into Yield EBITDA<\/h2>\n

With ASC margins shrinking<\/strong> across the industry, the performance gap between ASCs that treat billing as a back-office function and those that deploy a structured MBC Revenue Integrity Framework<\/strong><\/a> is widening every quarter. Revenue integrity is not a reporting upgrade \u2014 it is the operational infrastructure that connects every case performed in the OR to the maximum contracted reimbursement that case is entitled to collect. For ASCs collecting $1M\u2013$5M per month, the difference between billing and revenue integrity<\/strong> is $60,000\u2013$300,000 per month in recovered revenue \u2014 the exact figure that separates facilities whose margins are eroding from those whose margins are expanding despite the same 2026 reimbursement environment.<\/p>\n

As the leading medical billing company<\/strong> in the USA with 25+ years of specialized ASC Billing Service experience<\/a>, MBC operates a dedicated ASC Center of Excellence that engineers the financial performance metrics<\/strong> that CFOs and facility administrators actually need: net collection ratio by procedure category, Days in AR segmented by payer, implant capture rate by OR, and denial root-cause classification by CPT and payer \u2014 not an aggregate AR aging report that obscures where the leakage is occurring. Our medical billing services<\/strong><\/a> are system-agnostic \u2014 no EHR replacement, no implementation timeline, no disruption to OR scheduling.<\/p>\n

Where most billing vendors deliver monthly statements, MBC delivers net realized revenue growth<\/strong> through three operational pillars: payer variance detection that recovers contracted revenue payers are withholding, denial root-cause engineering<\/strong> that eliminates structural denial patterns before they compound, and real-time implant charge capture that closes the device revenue gap that silently erodes Yield EBITDA<\/strong> in every device-intensive specialty. The result: ASCs that partner with MBC consistently achieve a 30% reduction in Days in AR and a measurable improvement in the net collection ratio within 90 days of engagement.<\/p>\n

The starting point is a Complimentary 90-Day ASC Revenue Diagnostic<\/strong><\/a> \u2014 a structured review of your current net collection ratio, denial rates by payer and procedure category, ASCQR compliance status, and implant capture rate, all against industry benchmarks. The diagnostic identifies your specific sources of leakage and the monthly recovery potential from closing each one, before you commit to any billing change. For ASCs where ASC margins\u00a0<\/strong>are shrinking<\/strong> despite record case volume, the diagnostic turns<\/span>\u00a0that frustration into a recovery roadmap with a specific dollar figure attached.<\/p>\n

ASC Margins Shrinking? Volume Is Up \u2014 Make Sure the Revenue Actually Follows.<\/strong><\/p>\n

Medical Billers and Coders (MBC) delivers ASC Billing Services<\/strong>, Old AR Recovery<\/strong>, RCM Services<\/strong>, and Denial Management Services<\/strong> built specifically for ASCs navigating the 2026 reimbursement landscape \u2014 ASCQR compliance protocols, payer variance detection on all 573 new CPL procedures, and real-time implant charge capture\u201425+ years of ASC billing expertise. Dedicated account manager. No EHR change required.<\/p>\n

\u2192 Request Your 90-Day ASC Margin Diagnostic<\/strong><\/a><\/p>\n

Frequently Asked Questions: ASC Margins Shrinking in 2026<\/strong><\/h2>\n\n\n
Why are ASC margins shrinking in 2026 despite record case volume?<\/strong><\/strong>

ASC margins are compressing because costs are rising faster than reimbursement simultaneously across four categories: anesthesia stipends now required by 44% of ASCs, medical supply chain costs projected to increase 2.41%, a CMS payment update of only 2.6% against real cost inflation, and prior authorization requirements covering 46% of cases creating administrative expense and case cancellation risk that erodes EBITDA even when claims are paid.<\/p> <\/div>

What is the CMS 2026 ASC payment update, and is it enough to cover rising costs?<\/strong><\/strong>

CMS finalized a 2.6% ASC payment increase for 2026 (CMS-1834-FC) based on a 3.3% hospital market basket increase minus a 0.7% productivity adjustment, with a 2.0 percentage point reduction for ASCQR non-compliance; for most ASCs, the 2.6% increase is insufficient to offset simultaneous cost pressures in anesthesia, supplies, and prior authorization administration, creating a net negative margin impact of $17,000\u2013$134,000 per month for a $3M facility.<\/p> <\/div>

How do the 573 new ASC-covered procedures affect revenue in 2026?<\/strong><\/strong>

CMS added 573 codes to the ASC Covered Procedures List for 2026, creating genuine revenue opportunities in spine, cardiovascular, and musculoskeletal procedures \u2014 but commercial payers require 60\u2013180 days to update their own coverage policies after CMS approval, meaning ASCs billing newly eligible procedures without payer-specific verification face systematic denials during the transition period that convert volume growth into billing losses.<\/p> <\/div>

What is the WISeR prior authorization model, and which ASCs does it affect?<\/strong><\/strong>

CMS launched the Wasteful and Inappropriate Service Reduction (WISeR) Model on January 1, 2026, requiring AI-assisted prior authorization for 17 service categories, including electrical nerve stimulator implants, epidural steroid injections, percutaneous vertebral augmentation, and image-guided lumbar decompression in six states: Arizona, New Jersey, Ohio, Oklahoma, Texas, and Washington.<\/p> <\/div>

What revenue integrity actions protect ASC margins when reimbursement growth is limited?<\/strong><\/strong>

Four protocols protect ASC margins directly: ASCQR compliance verification to secure the full 2.6% payment update, payer variance detection on all 573 new CPL procedures before billing, pre-scheduling prior authorization verification to prevent case cancellations, and daily implant charge capture reconciliation against OR logs to prevent device revenue leakage from compounding across billing cycles.<\/p> <\/div> <\/div>\n\n\n\n

References<\/h2>\n\n\n\n